The Palliative Radiotherapy And Inflammation Study - PRAIS (PRAIS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02107664|
Recruitment Status : Active, not recruiting
First Posted : April 8, 2014
Last Update Posted : October 3, 2018
Radiation therapy (RT) is one of the primary treatments for bone cancer pain due to metastatic cancer disease. About 6 of 10 patients obtain pain relief from RT. There are no established predictors that can be used to select patients that respond to RT. This raises the need to identify potential clinical characteristics and biomarkers that may better select patients for RT. A similar argument can be stated for the development of cachexia; there are currently no predictors that can identify patients who will develop cachexia later in the cancer disease trajectory. Cancer symptoms can be related to inflammation. Both pain, cachexia and depression are associated with inflammation in experimental and preclinical studies . Still, the clinical data on the relationship between inflammation and pain or cachexia are sparse. This is especially true for longitudinal follow-up studies.
This study will include 1000 adult patients in a multicenter, multinational longitudinal observation study of patients who receive radiation therapy for bone cancer pain. Demographic data, clinical variables, genetic biomarkers and inflammatory substances will be assessed before start of RT. The primary analysis in the study is to identify potential predictors for pain relief from RT. During follow up the study will also explore for predictors for development of cachexia and which inflammatory substances that are associated with changes in pain intensity, depression and development of cachexia.
|Condition or disease||Intervention/treatment|
|Neoplasm Metastasis Bone Neoplasms||Radiation: Palliative RT for bone cancer pain|
|Study Type :||Observational|
|Actual Enrollment :||580 participants|
|Official Title:||The Palliative Radiotherapy And Inflammation Study: Palliative Radiotherapy of Bone Metastasis. Classification, Inflammatory Biomarkers, and Longitudinal Clinical Follow-up|
|Actual Study Start Date :||December 2013|
|Actual Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2018|
Radiation therapy for bone cancer pain
The group includes all cancer diagnoses, and different fractions of RT planned.
Radiation: Palliative RT for bone cancer pain
- Pain response [ Time Frame: 3 - 8 weeks ]
Complete response implies a numeric rate scale (NRS) worst pain of zero at the treated site on an 11-point rating scale, with no concomitant increase in analgesic intake.
Partial response is defined as either i) pain reduction of two or more at the treated site on the 11-point NRS worst pain rating scale together with no increase in analgesic intake, or ii) reduction in analgesic intake of at least 25 per cent from baseline without an increase in pain score at the treated site.
An "intermediate response" category represents any response other than complete or partial response or pain progression
- Cachexia [ Time Frame: 1 year ]Cachexia defined as a) Weight loss >5% over past 6 months (in absence of simple starvation); or b) body mass index (BMI) <20 and any degree of weight loss >2%; or c) Appendicular skeletal muscle index consistent with sarcopenia (males <7・26 kg/m2; females <5・45 kg/m2) and any degree of weight loss >2%
- Depression [ Time Frame: 1 year ]Depression symptoms last 2 weeks scored i patient Health Questionnaire (PHQ) - 9.
- Inflammatory Biomarkers [ Time Frame: 1 year ]Change in inflammatory biomarkers during longitudinal follow-up in relation to change in pain, depression and cachexia.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02107664
|Dept of Oncology, Oslo Universitetssykehus|
|Dept of Oncology, St Olavs Hospital|
|Trondheim, Norway, 7006|
|Dept of Oncology, Ålesund sjukehus|
|Study Director:||Pål Klepstad, phd md||Norwegian University of Science and Technology|